Maia climbs after positive data from lung cancer treatment trial

Maia Biotechnology

24/10/2023 17:05

** Shares of cancer drug developer Maia Biotechnology
 MAIA.A  rise ~9% to $2.13
    ** Co says its experimental drug THIO showed 100% disease
control rate (DCR) in second-line treatment of non-small cell
lung cancer during a mid-stage study
    ** DCR is defined as the percentage of patients with
advanced cancer whose therapeutic intervention has led to a
complete response, partial response or stable disease 
    ** Including session's move, shares down ~41.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))